2023 World Conference on Lung Cancer (Posters)-EP12.01. A Study of Aumolertinib Monotherapy or Combination Treated EGFR-mutated NSCLC Patients with Symptomatic Brain Metastases

EP12.01. A Study of Aumolertinib Monotherapy or Combination Treated EGFR-mutated NSCLC Patients with Symptomatic Brain Metastases - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to assess the efficacy of aumolertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with symptomatic brain metastases. The study included 33 patients with EGFR-mutated non-small cell lung cancer (NSCLC) and symptomatic brain metastases. Of these patients, 11 received aumolertinib as first-line treatment and 22 as posterior-line treatment. <br /><br />In the first-line treatment group, the majority of patients were female and had the 19del EGFR mutation. The objective response rate (ORR) was 81.8%, with 9 patients showing a confirmed partial response (PR), and the disease control rate (DCR) was 100%. The median progression-free survival (PFS) and overall survival (OS) were not reached, and the 12- and 24-month PFS rates were 81.8% and 63.6%, respectively. The 12- and 24-month OS rates were 90.9% and 81.8%, respectively.<br /><br />In the posterior-line treatment group, the ORR was 40.9% and the DCR was 100%, with 9 patients showing a confirmed PR and 13 showing stable disease. The median PFS was 12.1 months and the median OS was 32.0 months. The main treatment regimens in this group were aumolertinib monotherapy and aumolertinib combined with whole brain radiation therapy (WBRT).<br /><br />The study concluded that aumolertinib monotherapy or combination with local therapy improved survival time and neurological symptoms related to brain metastases and quality of life. This retrospective study provides evidence for the efficacy of aumolertinib in patients with symptomatic brain metastases in EGFR-mutated NSCLC.<br /><br />Keywords: aumolertinib, symptomatic brain metastases, EGFR.

Asset Subtitle

Xiaojuan Zhang

Meta Tag

Speaker Xiaojuan Zhang

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

aumolertinib

EGFR

brain metastases

NSCLC

first-line treatment

posterior-line treatment

PFS

monotherapy

combination therapy